Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 6/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581779 | 0.97 | OPRD1 (0.58) | OPRD1BACE1BACE2 | |
| SCHEMBL30320514 | 0.86 | TFPI (0.59) | — | |
| SCHEMBL30262067 | 0.86 | BACE1 (0.52) | BACE1 | |
| SCHEMBL29805358 | 0.86 | BACE1 (0.54) | OPRD1BACE1BACE2 | |
| SCHEMBL29836289 | 0.85 | TFPI (0.58) | — | |
| SCHEMBL30512724 | 0.84 | F2 (0.58) | — | |
| SCHEMBL29413128 | 0.83 | KISS1R (0.51) | OPRD1BACE1 | |
| SCHEMBL30912173 | 0.83 | GLP1R (0.52) | OPRD1 | |
| SCHEMBL30607469 | 0.82 | BACE1 (0.51) | OPRD1BACE1BACE2 | |
| SCHEMBL31688322 | 0.82 | VIPR2 (0.57) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250327097-A1 | ORGANISMS PRODUCING LESS CROTONIC ACID | GLOBAL BIOENERGIES (FR) | 2025-10-23 | — | — | US | claimed |
| EP-4573192-A1 | METHOD AND MEANS FOR ENGINEERING NON-RIBOSOMAL PEPTIDES | Johann-Wolfgang-Goethe-Universität Frankfurt am Main (DE) | 2025-06-25 | — | — | EP | claimed |
| US-20250027079-A1 | USE OF FANA ANTISENSE OLIGONUCLEOTIDES FOR THE PREVENTION AND MANAGEMENT OF HUANGLONGBING AND ZEBRA CHIP DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2025-01-23 | — | — | US | claimed |
| CN-119285727-A | Acyl carrier protein ACP65-74 and preparation method thereof | 天津凯莱英医药科技发展有限公司 | 2025-01-10 | — | — | CN | claimed |
| US-20240368659-A1 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | BIOSYNTIA APS (DK) | 2024-11-07 | — | — | US | claimed |
| EP-4399284-A1 | ORGANISMS PRODUCING LESS CROTONIC ACID | Global Bioenergies (FR) | 2024-07-17 | — | — | EP | claimed |
| EP-4370653-A2 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | Biosyntia ApS (DK) | 2024-05-22 | — | — | EP | claimed |
| WO-2024038117-A1 | METHOD AND MEANS FOR ENGINEERING NON-RIBOSOMAL PEPTIDES | JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT (DE) | 2024-02-22 | — | — | WO | claimed |
| EP-4168566-A1 | METHODS FOR PRODUCING BIOTIN IN GENETICALLY MODIFIED MICROORGANISMS | Biosyntia ApS (DK) | 2023-04-26 | — | — | EP | claimed |
| WO-2023031482-A1 | ORGANISMS PRODUCING LESS CROTONIC ACID | GLOBAL BIOENERGIES (FR) | 2023-03-09 | — | — | WO | claimed |
| WO-2023285585-A2 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | BIOSYNTIA APS (DK) | 2023-01-19 | — | — | WO | claimed |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-07-14 | — | — | US | claimed |
| EP-3090043-B1 | 3-HYDROXYISOVALERATE (HIV) SYNTHASE VARIANTS | GLOBAL BIOENERGIES (FR) | 2022-02-02 | — | — | EP | claimed |
| US-20260137736-A1 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | BIOMEDIT LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612428-B2 | Process for solid-phase peptide synthesis and device | KREUZER OLIVER JOHANNES (DE) | 2026-04-28 | — | — | US | disclosed |
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | GENOMATICA, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3945815-A1 | CRYOPRESERVATION AND CELL CULTURE MEDIA | Akron Biotechnology, LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-109628617-B | Nucleic acid reagent, kit, system and method for detecting drug resistance of mycobacterium tuberculosis | 北京卓诚惠生生物科技股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2022023765-A1 | METHOD FOR SCREENING FOR BIOACTIVE NATURAL PRODUCTS | UNIVERSITY OF WARWICK (GB) | 2022-02-03 | — | — | WO | disclosed |
| EP-3090043-B1 | 3-HYDROXYISOVALERATE (HIV) SYNTHASE VARIANTS | GLOBAL BIOENERGIES (FR) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | CYP4F11, CYP2F1, CYP4Z1 | OPRD1 978/4885BACE1 685/4885BACE2 650/4885 |
| US-20260137736-A1 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | FABP2, SLC10A2, ALPI | OPRD1 2959/4885BACE1 3778/4885BACE2 3600/4885 |
| US-12612428-B2 | Process for solid-phase peptide synthesis and device | MAX, SPATS2L, QPCTL | OPRD1 3753/4885BACE1 62/4885BACE2 421/4885 |
| US-20250027079-A1 | USE OF FANA ANTISENSE OLIGONUCLEOTIDES FOR THE PREVENTION AND MANAGEMENT OF HUANGLONGBING AND ZEBRA CHIP DISEASES | SLIRP, FBL, MYBBP1A | OPRD1 4444/4885BACE1 3258/4885BACE2 2832/4885 |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | OPRD1 3909/4885BACE1 2520/4885BACE2 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.